Vivtex

Oral Biologic Delivery

Vivtex combines automated whole-tissue culture systems, high-throughput screening technology, and AI to develop therapeutics with oral delivery methods to circumvent more invasive methods. They aim to identify, optimize, and develop molecules that maximize bioavailability and gastrointestinal absorption to create next generation oral therapeutics. They screen their oral therapeutics via porcine gastrointestinal tissue, which is genetically close to the human genome compared to smaller species like rodents. Through their analysis of drug transport using these tissue explants, they were able to predict oral drug absorption of the human gut. They are currently collaborating with 6 of the top 30 pharma companies to develop new oral therapies.